To the Editor: Vitiligo is not a fatal disease; however, it can have strong social and psychological impacts on the patients. Genetic susceptibility, autoimmunity, neural dysregulation, melanin self-destruction, and oxidative stress may be involved in the pathogenesis of vitiligo. Based on its clinical development, vitiligo can be divided into the progressive vitiligo (PV) or the stable vitiligo (SV). To date, at least 50 susceptible genes had been found in vitiligo.\[[@ref1]\] However, only a few genes presented a clear association with the high inherent risk of vitiligo and the protein levels of these genes were scarce. Recently, combination methods had been introduced in order to obtain better results. Nevertheless, no validated tool could confirm on the stage of vitiligo. Proteomics is a useful tool for large-scale screening of disease-related proteins. It could provide a better understanding of the biological and molecular events for this disease. Isobaric tag for relative and absolute quantitation (iTRAQ) is a systematic protein quantitative analytical method. It has the highest flux, the smallest system error, and the most powerful function for diagnosis, treatment, and prognosis. In this study, we identified differentially expressed proteins using iTRAQ-based proteomic technology and constructed an interaction network for SV and PV with the aim to identify potential group proteins as markers to distinguish between SV and PV.

All the patients and healthy controls were enrolled at the Dermatological Outpatient Clinic of the First Hospital of China Medical University from 2015 to 2016. Vitiligo was diagnosed clinically by experienced dermatologists. Staging of the disease was performed according to the Vitiligo Disease Activity Score (VIDA) in the *Consensus of Vitiligo Diagnosis and Treatment* (2014 edition) issued by the Dermatology Committee of Pigmentary Disease of the Chinese Association of Integrative Medicine. Patients with PV (VIDA score over 2 points) showed emergence of new skin lesions expansion of the original skin lesions or occurrence of the Koebner phenomenon within three months. Patients with SV were defined as those with stable lesions for at least one year. The sites and progression of the lesions and the extent of cutaneous involvement were documented.

Clinical information of the patients with PV and SV are presented in Supplementary Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Ten serum samples from each group were pooled together for proteomic experiments. The remaining 20 serum samples were used in Western blotting experiments for verification of results.

###### 

Characteristics of patients with PV

  Number       Gender   Age (years)   Time of new-onset   Site                        Koebner phenomenon   Family history
  ------------ -------- ------------- ------------------- --------------------------- -------------------- ----------------
  Patient 1    Male     17            Nearly 1 month      e, f, k, l                  Yes                  No
  Patient 2    Male     29            Nearly 3 months     a, b, c, e, f               Yes                  Yes
  Patient 3    Female   33            Nearly 1 month      a, b, c, e, f, g, j, k, l   Yes                  No
  Patient 4    Female   24            Nearly 1 month      e, f, k, l                  Yes                  No
  Patient 5    Female   19            Nearly 1 month      a, b, c, f, k, l            No                   Yes
  Patient 6    Male     41            Nearly 4 months     a, b, c, g, k, l            Yes                  No
  Patient 7    Female   38            Nearly 2 months     a, b, d, e, f, k, l         Yes                  No
  Patient 8    Male     29            Nearly 1 month      g, i, j                     No                   No
  Patient 9    Female   33            Nearly 3 months     a, b, c, d, e, f, g, k, l   Yes                  No
  Patient 10   Male     26            Nearly 6 months     e, f, k, l                  Yes                  No

The VIDA integral: Nearly 6 weeks appear new lesions or lesions expand (+4), nearly 3 months appear new lesions or lesions expand (+3), nearly 6 months appear new lesions or lesions expand (+2); nearly 1 year appear new lesions or lesions expand (+1). Score \>1 points is progression, \>4 points for the rapid progression. All patients have no autoimmune disease. Vitiligo in the progressive stage included 12 cases of sporadic vitiligo (40.0%), 10 cases of acrofacial (33.3%), and 8 cases of universal (26.7%), they are 5 males and 5 females. a: Head (3%); b: Face (3%); c: Neck (3%); d: Upperarm (7%); e: Forearm (6%); f: Hands (5%); g: Trunk (26%); h: Perineum (1%); i: Hip (5%); j: Thigh (21%); k: Shin (13%); l: Feet (7%). VIDA: Vitiligo Disease Activity Score; PV: Progressive vitiligo.

###### 

Characteristics of patients with SV

  Number       Gender   Age   Time of stable phase (years)   Site                           Koebner phenomenon   Family history
  ------------ -------- ----- ------------------------------ ------------------------------ -------------------- ----------------
  Patient 11   Male     27    \>10                           e, f, k, l                     No                   Yes
  Patient 12   Female   38    \>10                           a, b, c, e, f, g, i, j, k, l   No                   No
  Patient 13   Female   43    \>20                           a, b, c, e, f, l               No                   No
  Patient 14   Female   20    \>4                            a, b, c, e, f                  No                   No
  Patient 15   Female   16    \>5                            a, b, c, f, k, l               No                   No
  Patient 16   Male     33    \>10                           a, b, c, e, f, k, l            No                   No
  Patient 17   Male     47    \>10                           a, b, c, d, e, f, g, k, l      No                   No
  Patient 18   Female   34    \>20                           g, i, j                        No                   Yes
  Patient 19   Female   26    \>10                           g, i, j, k, l                  No                   No
  Patient 20   Male     29    \>10                           a, b, c, e, f, k, l            No                   No

The evaluation of the criterion in SV is set by disease activity score (VIDA). Depigmentation phase was stable for \>1 year (0 score), at the same time, there is spontaneous pigment regeneration (−1). All patients have no autoimmune disease. Vitiligo in the stable stage included 14 cases of sporadic vitiligo (46.7%), 8 cases of acrofacial (26.7%), 8 cases of universal (26.7%), they are 4 males and 6 females. a: Head (3%); b: Face (3%); c: Neck (3%); d: Upperarm (7%); e: Forearm (6%); f: Hands (5%); g: Trunk (26%); h: Perineum (1%); i: Hip (5%); j: Thigh (21%); k: Shin (13%); l: Feet (7%). VIDA: Vitiligo disease activity score; SV: Stable vitiligo.

Pooled serum samples from each group were prepared before proteomic analysis. The ProteoPrep Blue Albumin and IgG Depletion kit (Sigma-Aldrich, Co., St. Louis, MO, USA) were used to remove albumin, and IgG protein concentration was estimated using the BCA Protein Assay Kit (Thermo Scientific, Rockford, California, USA). Total proteins of each group were analyzed by iTRAQ (AB Sciex, Framingham, Massachusetts, USA), liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Protein samples (100 μg) were reduced, alkylated, and subjected to tryptic hydrolysis. iTRAQ labeling was performed using iTRAQ Reagents manufacturer\'s protocol. Each sample was labeled with the respective iTRAQ tags. All the labeled peptides were merged and evaporated to dryness in a vacuum centrifuge.

The iTRAQ labelled samples were firstly diluted to 100 μl with H2O buffer (NH~3~•H~2~O, pH=10) before high performance liquid chromatography on a Dionex Ultimate 3000 system (Dionex, Sunnyvale, CA, USA) at 25°C on a Gemini NX 3u C18 110A; 150.0 mm × 2.0 mm Phenomenex column, and Gemini 3u C6 Phenyl 110A; 100.0 mm × 2.0 mm column (all from Phenomenex, Torrance, CA, USA). The flow rate used for reversed-phase column separation was 0.2 ml/min with H~2~O (mobile Phase A) and 80% ACN (mobile Phase B). A solvent gradient system was used: 0--15 min, 5--10% B; 15--48 min, 15--25% B; 48--60 min, 25--37% B; 60--65 min, 37--95% B; and 65--70 min, 95% B. The elution was monitored by absorbance at 214/280 nm, and fractions were collected every 50 s. In total, 10 fractions were combined and dried.

Peptides were separated by a linear gradient according to the manufacture\'s instruction. MS analysis was performed on a Q Exactive system (Thermo Fisher Scientific, California, USA) in information-dependent mode. MS spectra were acquired across the mass range of 350--1800 m/z in high-resolution mode (\>35,000); a maximum of 20 precursors per cycle were chosen for fragmentation from each MS spectrum with a 120-ms minimum accumulation time for each precursor and dynamic exclusion for 10s. The tandem mass spectra were recorded in high-sensitivity mode (resolution \>175,000) with rolling collision energy and iTRAQ reagent collision energy adjustments.

Proteins extracted from the serum samples of 20 patients with SV, 20 patients with PV, and 20 healthy controls were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (11--15% acrylamide). After transferring the blots onto PVDF membranes and blocking overnight (5% skim milk and 0.05% Tween-20 in PBS), the primary antibody was added for 1 h, followed by PBS washing, addition of a secondary HRP-conjugated antibody, and development with a chemiluminescence detection system (ECL, Pierce, USA). Anti-plasma serine protease inhibitor (SERPINA5), hepatocyte growth factor activator (HGFAC), anti-leucine zipper protein 4 (LUZP4), and anti-phosphoinositide phospholipase C (PLCH2) were used (Abcam, USA).

The interaction network of differentially expressed proteins was constructed by the Cytoscape (National Institute of General Medical Sciences, USA), which is an open source software platform for visualizing molecular interaction networks and biological pathways and integrating these networks with annotations. The differentially expressed proteins involved in biological processes, molecular functions, cell components, and pathway enrichment were evaluated using the Cytoscape platform based on Gene Ontology (GO) terms. The corresponding *P* value analysis was simultaneously obtained using ReactomeFIViz (National Institute of General Medical Sciences).

The peptide data were analyzed with Protein Pilot Software 5.0 using the Paragon protein database search algorithm (AB Sciex, Framingham, Massachusetts, USA). The resulting MS/MS spectra were searched against the International Protein Index human sequence database (version 3.83). The parameters for the analysis were set as follows: Cys alkylation with methyl methanethiosulfonate, digestion with trypsin, and allowance of up to one missed trypsin cleavage. The false discovery rate (FDR) analysis was also performed using the integrated tools (FDR ≤0.01).

All the data were analyzed using Statistical Package for the Social Sciences Software (SPSS Inc., Chicago, IL, USA) version 16.0. The significant difference was analyzed by one-way analysis of variance (ANOVA). The gray value ratio of each band compared between the groups (SV or PV compared to control) was used to calculate the significant difference by least significant difference as a *post hoc* test. A value of *P* \< 0.05 was considered statistically significant.

In total, 171 differentially expressed proteins were identified through iTRAQ. Compared with the control group, there were 80 (42 upregulated and 38 downregulated) and 89 (56 upregulated and 33 downregulated) differentially expressed proteins in the SV and PV groups, respectively \[Supplementary Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\]. Among these differentially expressed proteins, 39 showed similar changes in both the SV and PV groups. Among them, the differentially expressed upregulated and downregulated proteins were 19 and 20. When the progressive stage was compared with the stable stage of vitiligo, 71 (23 upregulated and 48 downregulated) proteins were found to be differentially expressed \[[Supplementary Table 5](#T5){ref-type="table"}\].

###### 

Identification of differentially expressed proteins of SV samples versus control samples

  Accession number   Protein name                                                             Gene name       Mw           pI      Coverage (%)   Peptides (95%)   Unused protscore   SV ratio
  ------------------ ------------------------------------------------------------------------ --------------- ------------ ------- -------------- ---------------- ------------------ ----------
  B9DI82             Phosphoinositide phospholipase C (fragment)                              *PLCH2*         134,778.10   7.64    3.15           1                1.8                5.73
  P05154             Plasma serine protease inhibitor                                         *SERPINA5*      45,674.14    9.30    21.92          7                11.73              10.07
  A0A0B4J2B7         Protein IGHV3-30 (fragment)                                              *IGHV3-30*      12,946.63    9.10    84.62          39               4                  5.29
  P23083             Ig heavy chain V-I region V35                                            N/A             13,008.57    9.59    73.50          28               6.08               3.27
  P06331             Ig heavy chain V-II region ARH-77                                        N/A             16,228.27    8.45    26.71          29               2                  3.56
  A0A0C4DH31         Protein IGHV1-18 (fragment)                                              *IGHV1-18*      12,820.29    8.98    55.56          20               6.01               2.82
  P01876             Ig alpha-1 chain C region                                                *IGHA1*         37,654.23    6.08    79.04          191              35.61              4.23
  A0A075B6K4         HCG2043238 (fragment)                                                    *IGLV3-10*      12,628.89    4.72    59.83          17               10.2               2.37
  A0A0B4J2H0         Protein IGHV1-69-2 (fragment)                                            *IGHV1-69-2*    12,660.18    8.64    59.83          33               4                  1.80
  Q15485             Ficolin-2                                                                *FCN2*          34,000.76    6.31    24.60          9                8.1                2.59
  A0A075B6K9         Ig lambda-2 chain C regions (fragment)                                   *IGLC2*         11,236.38    6.91    99.06          84               20.51              3.40
  A0A0B4J1V0         Protein IGHV3-15 (fragment)                                              *IGHV3-15*      12,925.64    8.84    78.15          20               8.1                1.98
  A0A0C4DH67         Protein IGKV1-8 (fragment)                                               *IGKV1-8*       12,537.18    9.21    58.26          18               4.27               1.83
  A0A075B6N7         Ig alpha-2 chain C region (fragment)                                     *IGHA2*         36,590.95    5.86    67.35          72               10.04              2.33
  D6RF35             Vitamin D-binding protein                                                *GC*            53,020.02    5.38    84.45          81               4.01               1.81
  P06319             Ig lambda chain V-VI region EB4                                          N/A             14,146.57    4.85    39.69          10               4.87               1.69
  P81605             Dermcidin                                                                *DCD*           11,283.74    6.09    20.91          1                2.04               1.51
  Q08380             Galectin-3-binding protein                                               *LGALS3BP*      65,330.25    5.13    29.06          10               14.59              1.88
  Q04756             Hepatocyte growth factor activator                                       *HGFAC*         70,681.11    6.99    20.00          14               16.16              1.82
  P03951             Coagulation factor XI                                                    *F11*           70,108.40    8.47    17.76          8                8.34               1.75
  P01709             Ig lambda chain V-II region MGC                                          N/A             11,557.43    5.12    42.34          2                2                  1.92
  P06316             Ig lambda chain V-I region BL2                                           N/A             13,564.07    7.64    62.31          12               4.11               1.85
  P35908             Keratin, type II cytoskeletal 2 epidermal                                *KRT2*          65,432.11    8.07    24.10          13               17.64              1.65
  A0A0B4J231         Immunoglobulin lambda-like polypeptide 5                                 *IGLL5*         23,150.06    9.08    55.35          63               4.32               2.09
  A0A0C4DH41         Protein IGHV4-61 (fragment)                                              *IGHV4-61*      13,065.75    9.36    55.93          35               13.04              1.57
  A0A0G2JN06         Ig gamma-2 chain C region (fragment)                                     *IGHG2*         35,900.23    7.66    79.75          142              14.68              1.51
  A0A0C4DH38         Protein IGHV5-51 (fragment)                                              *IGHV5-51*      12,674.41    8.45    70.09          25               8.07               1.57
  Q71DI3             Histone H3.2                                                             *HIST2H3A*      15,387.84    11.27   34.56          3                3.9                1.74
  A0A0B4J1U2         Protein IGLV7-43 (fragment)                                              *IGLV7-43*      12,450.88    6.52    16.24          5                3.06               1.57
  B4E1Z4             Uncharacterized protein                                                  N/A             140,941.20   6.82    54.58          104              101.59             1.57
  P00734             Prothrombin                                                              *F2*            70,036.12    5.64    72.19          69               56.96              1.70
  P02042             Hemoglobin subunit delta                                                 *HBD*           16,055.28    7.84    90.48          33               11.89              1.64
  P01780             Ig heavy chain V-III region JON                                          N/A             12,319.98    9.39    60.87          10               2                  1.70
  A0A087WYJ9         Ig mu chain C region                                                     *IGHM*          65,700.17    6.52    66.44          118              55.83              1.55
  P02766             Transthyretin                                                            *TTR*           15,886.83    5.52    72.11          23               18.87              1.58
  P01703             Ig lambda chain V-I region NEWM                                          N/A             10,904.07    9.39    78.64          22               2.01               1.96
  P04196             Histidine-rich glycoprotein                                              *HRG*           59,577.63    7.09    46.67          24               24.58              1.59
  P00747             Plasminogen                                                              *PLG*           90,568.09    7.04    62.35          94               74.79              1.67
  P01031             Complement C5                                                            *C5*            188,303.00   6.11    44.93          66               91.04              1.57
  P14780             Matrix metalloproteinase-9                                               *MMP9*          78,457.32    5.69    12.31          6                10.76              1.58
  A0A0C4DH68         Protein IGKV2-24 (Fragment)                                              *IGKV2-24*      13,078.87    8.74    55.83          20               4.71               1.63
  P69905             Hemoglobin subunit alpha                                                 *HBA1*          15,257.36    8.72    60.56          24               9.73               1.54
  Q9P127             Leucine zipper protein 4                                                 *LUZP4*         35,936.42    9.47    3.83           2                2                  −4.09
  P35527             Keratin, type I cytoskeletal 9                                           *KRT9*          62,063.62    5.14    19.90          13               14.49              −4.10
  P02763             Alpha-1-acid glycoprotein 1                                              *ORM1*          23,511.27    4.93    53.73          57               22.45              −2.98
  P69891             Hemoglobin subunit gamma-1                                               *HBG1*          16,140.27    6.64    45.58          14               4.7                −3.12
  P19827             Inter-alpha-trypsin inhibitor heavy chain H1                             *ITIH1*         101,387.90   6.31    50.27          87               53.78              −1.84
  P0C0L4             Complement C4-A                                                          *C4A*           192,783.20   6.66    71.90          219              181.76             −1.66
  P27169             Serum paraoxonase/arylesterase 1                                         *PON1*          39,730.81    5.08    62.82          40               23.94              −2.23
  P02748             Complement component C9                                                  *C9*            63,172.73    5.43    49.37          32               35.29              −2.69
  O75636             Ficolin-3                                                                *FCN3*          32,902.61    6.20    36.12          15               13.22              −3.20
  P35858             Insulin-like growth factor-binding protein complex acid labile subunit   *IGFALS*        66,034.20    6.33    30.08          13               23.34              −2.03
  P02750             Leucine-rich alpha-2-glycoprotein                                        *LRG1*          38,177.44    6.45    37.46          15               17.79              −2.02
  P07996             Thrombospondin-1                                                         *THBS1*         129,381.40   4.71    30.94          37               50.97              −2.17
  P04259             Keratin, type II cytoskeletal 6B                                         *KRT6B*         60,066.25    8.09    23.05          10               8.03               −2.16
  P19652             Alpha-1-acid glycoprotein 2                                              *ORM2*          23,602.35    5.03    54.23          33               9.59               −2.20
  P0DJI8             Serum amyloid A-1 protein                                                *SAA1*          13,531.86    6.28    63.11          6                2.91               −2.19
  P20742             Pregnancy zone protein                                                   *PZP*           16,3861.00   5.97    37.52          119              31.65              −2.34
  P02741             C-reactive protein                                                       *CRP*           25,038.26    5.45    23.66          3                3.3                −2.07
  P18428             Lipopolysaccharide-binding protein                                       *LBP*           53,382.97    6.23    18.09          9                12.92              −2.20
  A0A0A6YYG9         Protein ARPC4-TTLL3                                                      *ARPC4-TTLL3*   71,718.39    5.59    6.40           2                2                  −1.57
  Q14624             Inter-alpha-trypsin inhibitor heavy chain H4                             *ITIH4*         103,356.20   6.51    65.59          110              85.05              −1.77
  Q13201             Multimerin-1                                                             *MMRN1*         138,108.60   8.15    8.63           5                5.48               −1.93
  P01011             Alpha-1-antichymotrypsin                                                 *SERPINA3*      47,650.31    5.33    66.19          86               43.42              −1.63
  P04264             Keratin, type II cytoskeletal 1                                          *KRT1*          66,037.95    8.15    29.35          21               26.61              −1.82
  A0A075B6K3         Protein IGLV2-11 (fragment)                                              *IGLV2-11*      12,643.88    6.69    51.26          5                4                  −1.84
  P23142             Fibulin-1                                                                *FBLN1*         77,213.47    5.07    29.16          16               21.44              −1.89
  Q16610             Extracellular matrix protein 1                                           *ECM1*          60,673.46    6.25    34.44          12               19.14              −1.68
  P04275             von Willebrand factor                                                    *VWF*           309,262.00   5.29    16.74          27               50.73              −1.57
  P02647             Apolipoprotein A-I                                                       *APOA1*         30,777.44    5.56    88.39          228              77.72              −1.53
  E7ES19             Thrombospondin-4                                                         *THBS4*         96,004.91    4.39    10.46          4                3.04               −1.62
  P19823             Inter-alpha-trypsin inhibitor heavy chain H2                             *ITIH2*         106,462.20   6.40    49.79          90               49.73              −1.58
  P06681             Complement C2                                                            *C2*            83,266.95    7.23    41.09          30               10.01              −1.73
  P01009             Alpha-1-antitrypsin                                                      *SERPINA1*      46,735.98    5.37    88.28          240              91.91              −1.49
  P25311             Zinc-alpha-2-glycoprotein                                                *AZGP1*         34,258.30    5.71    64.09          35               37.02              −1.73
  V9GYM3             Apolipoprotein A-II                                                      *APOA2*         14,914.10    8.43    63.16          52               28.49              −1.62
  A0A087WXI2         IgGFc-binding protein                                                    *FCGBP*         44,5207.00   5.16    7.45           10               18.84              −1.63
  P07339             Cathepsin D                                                              *CTSD*          44,551.72    6.10    11.89          2                2.02               −1.61
  Q06033             Inter-alpha-trypsin inhibitor heavy chain H3                             *ITIH3*         99,848.02    5.49    38.20          24               22.37              −1.52
  P55058             Phospholipid transfer protein                                            *PLTP*          54,738.80    6.53    31.03          10               15.38              −1.61

Mw: Molecular weight; PV: Progressive vitiligo; SV: Stable vitiligo; N/A: Not applicable; pI: Isoelectric point.

###### 

Identification of differentially expressed proteins of PV samples versus control samples

  Accession number   Protein name                                                 Gene name       Mw           pI     Coverage (%)   Peptides (95%)   Unused protscore   PV ratio
  ------------------ ------------------------------------------------------------ --------------- ------------ ------ -------------- ---------------- ------------------ ----------
  A0A024R6I7         Alpha-1-antitrypsin                                          *SERPINA1*      46,707.93    5.37   87.80          230              2                  39.25
  P05154             Plasma serine protease inhibitor                             *SERPINA5*      45,674.14    9.30   21.92          7                11.73              10.53
  Q04756             Hepatocyte growth factor activator                           *HGFAC*         70,681.11    6.99   20.00          14               16.16              2.55
  P00739             Haptoglobin-related protein                                  *HPR*           39,029.11    6.63   81.03          100              14.38              2.41
  P08779             Keratin, type I cytoskeletal 16                              *KRT16*         51,267.25    4.98   27.27          9                9.89               2.91
  P69905             Hemoglobin subunit alpha                                     *HBA1*          15,257.36    8.72   60.56          24               9.73               2.73
  P03951             Coagulation factor XI                                        *F11*           70,108.40    8.47   17.76          8                8.34               2.08
  Q15485             Ficolin-2                                                    *FCN2*          34,000.76    6.31   24.60          9                8.1                2.89
  A0A0B4J2H0         Protein IGHV1-69-2 (fragment)                                *IGHV1*-69-2    12,660.18    8.64   59.83          33               4                  1.70
  P01876             Ig alpha-1 chain C region                                    *IGHA1*         37,654.23    6.08   79.04          191              35.61              4.58
  P80108             Phosphatidylinositol-glycan- specific phospholipase D        *GPLD1*         92,335.35    5.91   28.45          17               30.27              1.84
  P04114             Apolipoprotein B-100                                         *APOB*          515,598.30   6.58   66.10          550              468.39             1.89
  K7ER74             Protein APOC4-APOC2                                          *APOC4-APOC2*   20,049.07    6.36   51.69          21               16                 2.17
  P06331             Ig heavy chain V-II region ARH-77                            N/A             16,228.27    8.45   26.71          29               2                  2.45
  A0A0B4J231         Immunoglobulin lambda-like polypeptide 5                     *IGLL5*         23,150.06    9.08   55.35          63               4.32               2.55
  B0YIW2             Apolipoprotein C-III                                         *APOC3*         12,815.43    7.90   47.01          36               12.61              2.47
  P02042             Hemoglobin subunit delta                                     *HBD*           16,055.28    7.84   90.48          33               11.89              2.10
  P23083             Ig heavy chain V-I region V35                                N/A             13,008.57    9.59   73.50          28               6.08               1.94
  P0C0L5             Complement C4-B                                              *C4B*           192,749.20   6.89   71.56          220              8.82               2.77
  P55056             Apolipoprotein C-IV                                          *APOC4*         14,552.90    9.19   49.61          6                5.38               2.10
  P08697             Alpha-2-antiplasmin                                          *SERPINF2*      54,565.11    5.87   43.79          29               19.89              1.58
  P06396             Gelsolin                                                     *GSN*           85,696.47    5.90   53.07          53               47.75              2.02
  A0A075B6N7         Ig alpha-2 chain C region (fragment)                         *IGHA2*         36,590.95    5.86   67.35          72               10.04              2.24
  P00734             Prothrombin                                                  *F2*            70,036.12    5.64   72.19          69               56.96              1.81
  P68871             Hemoglobin subunit beta                                      *HBB*           15,998.21    6.74   82.31          43               24.33              2.09
  P10909             Clusterin                                                    *CLU*           52,494.01    5.89   51.22          63               34.68              1.65
  P04196             Histidine-rich glycoprotein                                  *HRG*           59,577.63    7.09   46.67          24               24.58              2.17
  B4E1Z4             Uncharacterized protein                                      N/A             140,941.20   6.82   54.58          104              101.59             2.14
  P19652             Alpha-1-acid glycoprotein 2                                  *ORM2*          23,602.35    5.03   54.23          33               9.59               1.77
  F5H7G1             Complement component C8 beta chain                           *C8B*           61,230.52    7.86   30.61          9                18.49              2.48
  P00742             Coagulation factor X                                         *F10*           54,731.14    5.68   37.50          13               23.06              1.73
  A0A0C4DH41         Protein IGHV4-61 (fragment)                                  *IGHV4-61*      13,065.75    9.36   55.93          35               13.04              1.60
  P08519             Apolipoprotein (a)                                           *LPA*           501,314.20   5.58   39.78          20               29.93              1.56
  A0A075B6K9         Ig lambda-2 chain C regions (fragment)                       *IGLC2*         11,236.38    6.91   99.06          84               20.51              2.01
  P08603             Complement factor H                                          *CFH*           139,095.00   6.21   59.38          138              120.45             1.76
  P04259             Keratin, type II cytoskeletal 6B                             *KRT6B*         60,066.25    8.09   23.05          10               8.03               1.55
  Q12805             EGF-containing fibulin-like extracellular matrix protein 1   *EFEMP1*        54,640.10    4.95   14.81          5                8.01               1.69
  E9PHK0             Tetranectin                                                  *CLEC3B*        17,793.93    4.96   66.25          15               10.07              1.59
  P08493             Matrix Gla protein                                           *MGP*           12,353.06    9.71   14.56          1                2                  1.50
  P43652             Afamin                                                       *AFM*           69,068.41    5.64   58.93          46               52.35              1.99
  O00391             Sulfhydryl oxidase 1                                         *QSOX1*         82,576.74    9.13   14.59          4                7.52               1.77
  P20851             C4b-binding protein beta chain                               *C4BPB*         28,357.18    5.05   38.89          7                9.3                1.68
  P01031             Complement C5                                                *C5*            188,303.00   6.11   44.93          66               91.04              1.94
  A0A087WTM7         Apolipoprotein B-100                                         *APOB*          489,827.10   6.69   67.61          536              2                  1.61
  P01011             Alpha-1-antichymotrypsin                                     *SERPINA3*      47,650.31    5.33   66.19          86               43.42              1.53
  A0A075B6K4         HCG2043238 (fragment)                                        *IGLV3-10*      12,628.89    4.72   59.83          17               10.2               1.58
  P14780             Matrix metalloproteinase-9                                   *MMP9*          78,457.32    5.69   12.31          6                10.76              1.66
  P05546             Heparin cofactor 2                                           *SERPIND1*      57,069.95    6.41   58.72          52               41.5               1.75
  P02765             Alpha-2-HS-glycoprotein                                      *AHSG*          39,324.24    5.43   64.31          72               35.09              1.73
  P01019             Angiotensinogen                                              *AGT*           53,153.57    5.87   41.24          32               21.65              1.67
  Q14624             Inter-alpha-trypsin inhibitor heavy chain H4                 *ITIH4*         103,356.20   6.51   65.59          110              85.05              1.73
  P19827             Inter-alpha-trypsin inhibitor heavy chain H1                 *ITIH1*         101,387.90   6.31   50.27          87               53.78              1.62
  A0A0C4DH68         Protein IGKV2-24 (fragment)                                  *IGKV2-24*      13,078.87    8.74   55.83          20               4.71               1.59
  P02647             Apolipoprotein A-I                                           *APOA1*         30,777.44    5.56   88.39          228              77.72              1.56
  P05160             Coagulation factor XIII B chain                              *F13B*          75,509.92    6.01   50.08          31               42                 1.53
  P06316             Ig lambda chain V-I region BL2                               N/A             13,564.07    7.64   62.31          12               4.11               1.66
  Q14019             Coactosin-like protein                                       *COTL1*         15,944.79    5.54   11.27          1                2                  −14.79
  A0A087WYJ9         Ig mu chain C region                                         *IGHM*          65,700.17    6.52   66.44          118              55.83              −9.37
  P01591             Immunoglobulin J chain                                       *JCHAIN*        18,098.40    5.12   70.44          15               9.66               −5.02
  Q92820             Gamma-glutamyl hydrolase                                     *GGH*           35,963.95    6.66   29.25          4                6.3                −2.55
  O43866             CD5 antigen-like                                             *CD5L*          38,087.45    5.28   44.96          18               21.83              −2.96
  Q9P127             Leucine zipper protein 4                                     *LUZP4*         35,936.42    9.47   3.83           2                2                  −3.96
  P04278             Sex hormone-binding globulin                                 *SHBG*          43,778.68    6.22   34.33          10               13.7               −2.67
  A0A0C4DH43         Uncharacterized protein (fragment)                           N/A             13,312.31    8.50   35.29          2                2.07               −3.28
  A0A0G2JPD4         Ig gamma-4 chain C region (fragment)                         *IGHG4*         35,940.14    7.18   73.09          175              6.07               −2.35
  P02750             Leucine-rich alpha-2-glycoprotein                            *LRG1*          38,177.44    6.45   37.46          15               17.79              −2.36
  A0A0B4J1X5         Protein IGHV3-74 (fragment)                                  *IGHV3-74*      12,839.47    8.91   83.76          104              3.38               −4.07
  P05109             Protein S100-A8                                              *S100A8*        10,834.38    6.51   39.78          6                8.75               −2.39
  P07996             Thrombospondin-1                                             *THBS1*         129,381.40   4.71   30.94          37               50.97              −2.06
  P00738             Haptoglobin                                                  *HP*            45,204.78    6.13   88.18          235              70.99              −1.85
  P06702             Protein S100-A9                                              *S100A9*        13,241.85    5.71   49.12          4                7.05               −2.00
  A0A0C4DH67         Protein IGKV1-8 (fragment)                                   *IGKV1-8*       12,537.18    9.21   58.26          18               4.27               −1.84
  P40197             Platelet glycoprotein V                                      *GP5*           60,958.46    9.73   12.86          4                4.72               −1.92
  Q06033             Inter-alpha-trypsin inhibitor heavy chain H3                 *ITIH3*         99,848.02    5.49   38.20          24               22.37              −2.05
  Q8IVF4             Dynein heavy chain 10, axonemal                              *DNAH10*        514,834.70   5.64   6.15           3                2.03               −2.03
  A0A087WUS7         Ig delta chain C region                                      *IGHD*          42,352.35    8.38   42.71          16               11.8               −2.75
  P07339             Cathepsin D                                                  *CTSD*          44,551.72    6.10   11.89          2                2.02               −2.02
  O75636             Ficolin-3                                                    *FCN3*          32,902.61    6.20   36.12          15               13.22              −1.64
  P35527             Keratin, type I cytoskeletal 9                               *KRT9*          62,063.62    5.14   19.90          13               14.49              −1.71
  P02776             Platelet factor 4                                            *PF4*           10,844.83    8.93   29.70          2                4                  −1.80
  P02748             Complement component C9                                      *C9*            63,172.73    5.43   49.37          32               35.29              −1.50
  P69891             Hemoglobin subunit gamma-1                                   *HBG1*          16,140.27    6.64   45.58          14               4.7                −1.52
  P83593             Ig kappa chain V-IV region STH (fragment)                    N/A             12,060.29    7.94   71.56          16               2.01               −1.77
  P0DJI8             Serum amyloid A-1 protein                                    *SAA1*          13,531.86    6.28   63.11          6                2.91               −1.70
  P18428             Lipopolysaccharide-binding protein                           *LBP*           53,382.97    6.23   18.09          9                12.92              −1.51
  P22792             Carboxypeptidase N subunit 2                                 *CPN2*          60,555.93    5.63   26.61          15               14.3               −1.70
  P20742             Pregnancy zone protein                                       *PZP*           163,861.00   5.97   37.52          119              31.65              −1.53
  P01770             Ig heavy chain V-III region NIE                              N/A             12,898.45    9.75   54.62          24               6.02               −1.69
  P06313             Ig kappa chain V-IV region JI                                N/A             14,632.35    6.15   71.43          51               13.34              −1.60

Mw: Molecular weight; PV: Progressive vitiligo; N/A: Not applicable; pI: Isoelectric point.

###### 

Differentially expressed proteins occurring in PV compared with SV

  Accession number   Protein name                                        Gene name    Mw           Coverage (%)   Peptides (95%)   Unused protscore   PV/SV ratio
  ------------------ --------------------------------------------------- ------------ ------------ -------------- ---------------- ------------------ -------------
  A0A087WYJ9         Ig mu chain C region                                *IGHM*       65,700.17    66.44          118              55.83              12.47
  Q14019             Coactosin-like protein                              *COTL1*      15,944.79    11.27          1                2                  19.41
  A0A0B4J1X5         Protein IGHV3-74 (fragment)                         *IGHV3-74*   12,839.47    83.76          104              3.38               5.97
  P01591             Immunoglobulin J chain                              *JCHAIN*     18,098.40    70.44          15               9.66               4.83
  A0A087WUS7         Ig delta chain C region                             *IGHD*       42,352.35    42.71          16               11.8               4.66
  A0A0C4DH67         Protein IGKV1-8 (fragment)                          *IGKV1-8*    12,537.18    58.26          18               4.27               2.78
  O43866             CD5 antigen-like                                    *CD5L*       38,087.45    44.96          18               21.83              2.65
  P04278             Sex hormone-binding globulin                        *SHBG*       43,778.68    34.33          10               13.7               2.23
  A0A0C4DH31         Protein IGHV1-18 (fragment)                         *IGHV1-18*   12,820.29    55.56          20               6.01               2.75
  P01770             Ig heavy chain V-III region NIE                     *IGHA1*      12,898.45    54.62          24               6.02               2.09
  D6RF35             Vitamin D-binding protein                           *GC*         53,020.02    84.45          81               4.01               1.66
  O43866             CD5 antigen-like                                    *CD5L*       38,087.45    44.96          18               21.83              2.65
  P04278             Sex hormone-binding globulin                        *SHBG*       43,778.68    34.33          10               13.7               2.23
  A0A0C4DH43         Uncharacterized protein (fragment)                  *N/A*        13,312.31    35.29          2                2.07               3.70
  A0A087WUS7         Ig delta chain C region                             *IGHD*       42,352.35    42.71          16               11.8               4.66
  P05109             Protein S100-A8                                     *S100A8*     10,834.38    39.78          6                8.75               1.91
  P01709             Ig lambda chain V-II region MGC                     N/A          11,557.43    42.34          2                2                  1.85
  P23083             Ig heavy chain V-I region V35                       N/A          13,008.57    73.50          28               6.08               1.58
  P01780             Ig heavy chain V-III region JON                     N/A          12,319.98    60.87          10               2                  1.67
  A0A0C4DH31         Protein IGHV1-18 (fragment)                         *IGHV1-18*   12,820       55.56          45               6.01               2.75
  P06702             Protein S100-A9                                     *S100A9*     13,241.85    49.12          4                7.05               1.54
  P60709             Actin, cytoplasmic 1                                *ACTB*       41,737       6              31               35.33              1.63
  A0A075B6K9         Ig lambda-2 chain C regions (fragment)              *IGLC2*      11,236.38    99.06          84               20.51              1.91
  A0A024R6I7         Alpha-1-antitrypsin                                 *SERPINA1*   46,707.93    87.80          230              2                  −51.52
  P0C0L5             Complement C4-B                                     *C4B*        19,2749.20   71.56          220              8.82               −2.86
  P02763             Alpha-1-acid glycoprotein 1                         *ORM1*       23,511.27    53.73          57               22.45              −3.94
  P0C0L4             Complement C4-A                                     *C4A*        192,783.20   71.90          219              181.76             −1.82
  P19652             Alpha-1-acid glycoprotein 2                         *ORM2*       23,602.35    54.23          33               9.59               −3.91
  P33908             Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA   *MAN1A1*     72,969       13.17          4                6.27               −3.53
  P04259             Keratin, type II cytoskeletal 6B                    *KRT6B*      60,066.25    23.05          10               8.03               −2.99
  P19827             Inter-alpha-trypsin inhibitor heavy chain H1        *ITIH1*      101,387.90   50.27          87               53.78              −2.58
  P01011             Alpha-1-antichymotrypsin                            *SERPINA3*   47,650.31    66.19          86               43.42              −2.13
  P27169             Serum paraoxonase/arylesterase 1                    *PON1*       39,730.81    62.82          40               23.94              −2.58
  Q14624             Inter-alpha-trypsin inhibitor heavy chain H4        *ITIH4*      103,356.20   65.59          110              85.05              −3.49
  F5H7G1             Complement component C8 beta chain                  *C8B*        61,230.52    30.61          9                18.49              −3.162
  P23142             Fibulin-1                                           *FBLN1*      77,213.47    29.16          16               21.44              −1.74
  P04275             von Willebrand factor                               *VWF*        309,262.00   16.74          27               50.73              −1.91
  P08779             Keratin, type I cytoskeletal 16                     *KRT16*      51,267.25    27.27          9                9.89               −3.22
  P02741             C-reactive protein                                  *CRP*        25,038.26    23.66          3                3.3                −2.88
  P69891             Hemoglobin subunit gamma-1                          *HBG1*       16,140.27    45.58          14               4.7                −1.87
  P08519             Apolipoprotein (a)                                  *LPA*        501,314.20   39.78          20               29.93              −1.82
  P68871             Hemoglobin subunit beta                             *HBB*        15,998.21    82.31          43               24.33              −1.87
  P35527             Keratin, type I cytoskeletal 9                      *KRT9*       62,063.62    19.90          13               14.49              −2.81
  P19823             Inter-alpha-trypsin inhibitor heavy chain H2        *ITIH2*      106,462.20   49.79          90               49.73              −1.91
  P36980             Complement factor H-related protein 2               *CFHR2*      30,651       41.85          7                6                  −1.91
  Q16610             Extracellular matrix protein 1                      *ECM1*       60,673.46    34.44          12               19.14              −2.07
  P04264             Keratin, type II cytoskeletal 1                     *KRT1*       66,037.95    29.35          21               26.61              −2.29
  P02647             Apolipoprotein A-I                                  *APOA1*      30,777.44    88.39          228              77.72              −2.94
  P05546             Heparin cofactor 2                                  *SERPIND1*   57,069.95    58.72          52               41.5               −1.61
  P06732             Creatine kinase M-type                              *CKM*        43,101       5.512          1                2                  −1.50
  P55056             Apolipoprotein C-IV                                 *APOC4*      14,552.90    49.61          6                5.38               −1.80
  Q9UHG3             Prenylcysteine oxidase 1                            *PCYOX1*     56,640       15.45          5                8.78               −1.63
  P01042             Kininogen-1                                         *KNG1*       71,957       55.12          106              54.98              −2.33
  P06396             Gelsolin                                            *GSN*        85,696.47    53.07          53               47.75              −1.51
  P02748             Complement component C9                             *C9*         63,172.73    49.37          32               35.29              −1.91
  A0A0A0MR46         RNA-binding protein 44                              *RBM44*      118,116      4.848          2                2                  −1.54
  P29622             Kallistatin                                         *SERPINA4*   48,542       49.65          24               27.74              −1.74
  P36955             Pigment epithelium-derived factor                   *SERPINF1*   46,312       57.89          17               26.25              −1.85
  B0YIW2             Apolipoprotein C-III                                *APOC3*      12,815.43    47.01          36               12.61              −1.82
  C9JF17             Apolipoprotein D (fragment)                         *APOD*       24,158       33.49          25               16.88              −3.25
  P00450             Ceruloplasmin                                       *CP*         12,2205      69.86          169              102.07             −1.89
  P05155             Plasma protease C1 inhibitor                        *SERPING1*   55,154       55.6           49               36.17              −1.54
  P06727             Apolipoprotein A-IV                                 *APOA4*      45,399       78.79          71               53.32              −1.54
  P20742             Pregnancy zone protein                              *PZP*        163,861.00   37.52          119              31.65              −1.57
  P01009             Alpha-1-antitrypsin                                 *SERPINA1*   46,735.98    88.28          240              91.91              −2.00
  P05160             Coagulation factor XIII B chain                     *F13B*       75,509.92    50.08          31               42                 −2.27
  O00391             Sulfhydryl oxidase 1                                *QSOX1*      82,576.74    14.59          4                7.52               −1.53
  O75636             Ficolin-3                                           *FCN3*       32,902.61    36.12          15               13.22              −2.70
  P02751             Fibronectin                                         *FN1*        26,2625      55.28          186              151.63             −2.07
  P02649             Apolipoprotein E                                    *APOE*       36,154       50.08          31               42                 −2.05
  P00739             Haptoglobin-related protein                         *HPR*        39,029.11    81.03          100              14.38              −2.01

Mw: Molecular weight; PV: Progressive vitiligo; SV: Stable vitiligo; N/A: Not applicable.

The differentially expressed proteins in the SV and PV groups were analyzed based on their GO clustering using the Cytoscape platform \[Supplementary Figures 1 and 2\]. The significance of the first 15 annotated functions was ranked according to the *P* values. The differently expressed proteins were categorized based on their molecular function, biological process, pathway enrichment, and cell component.

###### 

Categorization of differentially expressed proteins of progressive vitiligo compared to control. (a) The top 15 proteins with molecular function. (b) The top 15 proteins involved in biological processes. (c) The top 15 proteins in pathway enrichment. (d) The top 15 proteins of cell component. The log-transformed enrichment scores for molecular function, biological process, pathway enrichment, and cell component are indicated on the x axis.

###### 

Click here for additional data file.

###### 

Categorization of differentially expressed proteins of stable vitiligo compared to control. (a) The top 15 proteins with molecular function. (b) The top 15 proteins involved in biological processes. (c) The top 15 proteins in pathway enrichment. (d) The top 15 proteins of cell component. The log-transformed enrichment scores for molecular function, biological process, pathway enrichment and cell component are indicated on the x axis.

###### 

Click here for additional data file.

In the SV group, molecular function of the differentially expressed proteins included immunoglobulin (Ig) receptor binding, antigen binding, phosphatidylcholine binding, serine-type endopeptidase inhibitor activity, endopeptidase inhibitor activity, Ig binding, protease binding, complement component C1q binding, serine-type endopeptidase activity, oxygen transporter activity, glycoprotein binding, heparin binding, proteoglycan binding, low-density lipoprotein particle binding, and laminin binding proteins, as compared to the controls. PV group expressed the above proteins similar to those in the SV group, except that had no differential expression of complement component C1q binding, proteoglycan binding, low-density lipoprotein particle binding, and laminin binding. In addition, hemoglobin binding, haptoglobin binding, arachidonic acid binding, Toll-like receptor 4 binding, peptidoglycan binding, and heme binding proteins were also differentially expressed in the PV group.

Enrichment in pathway showed that differentially expressed proteins for both the vitiligo stages were involved in complement cascade, clotting cascade, sequestering of ions, and reverse cholesterol transport. However, amb2 integrin signaling and retinoid metabolism pathway were only identified in the progressive stage. The differentially expressed proteins in the biological process were those involved in complement activation, B cell and phagocytosis recognition, and innate immune response of both the vitiligo groups. Differentially expressed proteins related to responses to bacterium and the acute-phase process were detected in PV. The differentially expressed proteins related to cell components included proteins involved in extracellular components such as exosomes, Ig complexes, and the related matrix, in both the vitiligo groups. Functional proteins involved in the acute-phase response, such as the sequestering of ions, reverse lipid transport, and oxygen transport, were markedly highly expressed in the PV group, indicating that these proteins and their molecular functions and pathways may play primary roles in the pathogenesis of vitiligo.

Based on the results obtained from the iTRAQ-based proteomic analyses, the four most prominent differentially expressed proteins were reexamined by Western blotting. The two proteins (SERPINA5 and HGFAC) were upregulated in both the stages of vitiligo. SERPINA5 expression was significantly different in both the stages of vitiligo (SV vs. control, *P* \< 0.05; PV vs. control, *P* \< 0.05). In addition, PLCH2 expression was upregulated in the SV (SV vs. control, *P* \< 0.05) and LUZP4 was significantly downregulated in the PV (PV vs. control, *P* \< 0.01) \[[Figure 1](#F1){ref-type="fig"}\].

![The differential expression of four proteins in the different stages of vitiligo and controls. (a) Each column represents one group, and the groups were as follows: controls, patients with stable, and those with progressive patients. Beta-actin was used as the loading control. (b) The gray value ratio of each band compared between the groups (SV or PV compared with control) was used to calculate the significant differences by one-way analysis of variance. \*Represents that the difference is statistically significant in PLCH2 (*P* \< 0.05, SV vs. control);^†^ represents that the difference is statistically significant in LUZP4 (*P* \< 0.01, PV vs. control); ^‡^represents that the difference is statistically significant in SERPINA5 (*P* \< 0.05, SV vs. control and PV vs. control). SV: Stable vitiligo; PV: Progressive vitiligo; HGFAC: Hepatocyte growth factor activator; LUZP4: Leucine zipper protein 4; PLCH2: Phosphoinositide phospholipase C; SERPINA5: Plasma serine protease inhibitor.](CMJ-131-480-g001){#F1}

To better understand the mechanism underlying the pathogenesis of vitiligo, a protein interaction network for the differentially expressed proteins identified in the SV and PV groups was constructed using Cytoscape. The proteins marked with circles and different colors were identified in our analysis, and those marked with boxes are the linker proteins added by the Cytoscape platform \[Supplementary Figure 3\].

###### 

Protein interaction network of vitiligo. (a) Protein interaction network in stable vitiligo; (b) protein interaction network of progressive vitiligo. The proteins marked with circles and different colors were identified, and those marked with boxes are the linker proteins added by the Cytoscape platform.

###### 

Click here for additional data file.

Vitiligo is a common chronic acquired disease characterized by depigmentation. Currently, no specific curative therapy and no satisfactory method are available to predict or control the progression of the disease. Proteomics is a feasible approach for large-scale screening of vitiligo-related proteins to elucidate its pathogenesis. The present study employed iTRAQ-based quantitative proteomic tools to identify vitiligo-related proteins in the serum of patients with vitiligo. Disadvantage of this method is that the differentially expressed proteins identified might not fully represent the differentially expressed proteins in the independent sample. However, we generally choose the intersection of different proteins identified in the mixed samples and then selected individual samples to validate the proteomic results by Western blotting experiment. This method has also been proved to be reasonable and feasible in several reports. Our results revealed differentially expressed proteins in the vitiligo samples. Among them, 39 differentially expressed proteins were detected in both the vitiligo groups.

Autoimmunity is believed to be the primary cause of vitiligo. In our study, we identified many Ig heavy chain V proteins and Ig chain C proteins that were differentially expressed in SV and PV compared with the controls. We also identified the IgA complex significantly differentially expressed in both the stages of vitiligo compared to the controls from the cell component analysis. Therefore, the increased or decreased plasma levels of Ig heavy chain V or chain C might be potential group proteins requiring further investigation. Our proteomic analysis also showed increased levels of apolipoproteins (i.e., apolipoprotein A1, apolipoprotein A2, and apolipoprotein B) and decreased levels of serum paraoxonase/arylesterase 1 (PON1). These proteins were also analyzed to relate with lipid digestion, mobilization, and transport pathway. Pietrzak *et al*.\[[@ref2]\] reported that lipid metabolism was disrupted in vitiligo-affected children, possibly resulting from disrupted metabolic processes in the adipose tissue as well as oxidative stress. In our study, we found that PON1 levels were decreased in SV but not in PV. This finding indicates that PON1 may decrease when patients are in a stable condition.

Zinc-alpha-2-glycoprotein, an essential component of numerous proteins involved in biological defense mechanisms and functioning against oxidative stress, is differentially expressed in patients with SV. Some of these identified proteins are Zn^(2+)^ dependent, such as the plasma protein histidine-rich glycoprotein.\[[@ref3]\] Thus, we propose that zinc ion-binding proteins may play a role in the pathogenesis of vitiligo. In addition to the proteins involved in zinc ion binding, some of the identified proteins were involved in calcium ion binding, such as PLCH2 and vitamin D-binding protein. The results of Western blotting test revealed that PLCH2 levels were increased in both the stages of vitiligo, especially in SV. These results showed that proteins with functions related to sequestering calcium ions and reverse cholesterol transport were expressed at markedly high levels in the PV group. There are reports in the literature that polymorphisms in the vitamin D receptor are associated with vitiligo.\[[@ref4]\] Clinical trials have also shown that the plasma levels of 25-hydroxy vitamin D and calcium are significantly decreased in patients with vitiligo. Ongoing studies continue to uncover potential roles for the components of the neurosensory system in the skin homeostasis and disease states.

In addition, interestingly, proteins involved in other pathways were identified and further verified through Western blotting. SERPINA5 protein, a negative regulator of the Toll pathway, was increased in both SV and PV. It seemed to be associated with micropapillary growth and the invasive phenotype of serious vitiligo that had protease inhibitor-independent activity. The expression and role of serine-type endopeptidase inhibitors in the differentiation of human skin pigmentation remains elusive. Some studies have identified a serine-type protease inhibitor related to palmitoyltransferase that has an effect on melanogenesis.\[[@ref5]\] Among other known serine protease inhibitors (SERPINs), the enhanced stability of PAI-1 might play a role in the development of autoimmune disease and the pathophysiology of vitiligo.

Moreover, another protein HGFAC was identified and validated in the serum of patients with vitiligo. This protein has serine-type endopeptidase activity and was found to play a role in malignant melanoma progression. Interestingly, LUZP4 levels were found to be decreased in both the vitiligo stages compared to those in the controls. Although LUZP4 was not associated with vitiligo, it has been frequently reported to be activated in melanoma, where it is required for growth.\[[@ref6]\] LUZP4 may function to promote the export of mRNAs, which would normally function to export proteins. Thus, it is possible that LUZP4 could also affect melanocyte cell growth.

In conclusion, our findings indicated that the autoimmunity proteins, lipid metabolism, oxidative stress proteins (Ig heavy chain V and C, HBB, HBG1, and HBA1), ion-dependent proteins (zinc-alpha-2-glycoprotein, PLCH2, and vitamin D-binding protein), and serine-type inhibitor proteins (increases in SERPINA5 and decreases in LUZP4) might be involved in the pathogenesis of vitiligo. Even though the sample size was small, the differentially expressed proteins that were identified might provide useful information for the diagnosis of early-stage vitiligo prior to the appearance of severe symptoms or for the elucidation of the pathophysiological mechanism.
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